Table 5.

Lack of association of DR15 and TNF -308 and TNF -863 SNPs with outcome among Caucasian patients with CML.

Determinant	Overall Mortality	Relapse	NRM	Acute GVHD (II–IV)
TNF -308
GG	1	1	1	1
AG	0.97 (0.74–1.28, p=.85)	1.31 (0.89–1.91, p=.17)	0.99 (0.71–1.36, p=.93)	0.82 (0.51–1.33, p=.43)
AA	0.85 (0.40–1.83, p=.68)	0.85 (0.27–2.74, p=.79)	0.82 (0.33–2.01, p=.82)	0.86 (0.24–3.05, p=.81)
TNF -863
CC	1	1	1	1
AC	1.06 (0.81–1.40, p=.67)	1.32 (0.90–1.94, p=.16)	0.97 (0.70–1.36, p=.87)	0.86 (0.53–1.41, p=.56)
AA	1.14 (0.53–2.45, p=.74)	0.89 (0.21–3.66, p=.87)	1.06 (0.43–2.65, p=.89)	0.52 (0.12–2.32, p=.39)
DR15
absent	1	1	1	1
present	0.92 (0.68–1.23, p=.55)	0.98 (0.65–1.48, p=.91)	0.92 (0.65–1.31, p=.65)	1.14 (0.68–1.89, p=.63)

Values listed are hazard (for overall mortality, relapse, NRM) or odds ratios (for GVHD) (95% CI, p-value).

CI=confidence interval; GVHD=graft-versus-host disease; NRM=non-relapse mortality; TNF=tumor necrosis factor α.